Phase I and pharmacokinetic study of ecteinascidin-743, a new marine compound, administered as a 24-hour continuous infusion in patients with solid tumors

Journal of Clinical Oncology

Volumn 19, Issue 5, 2001, Pages 1256-1265

  Taamma, A ^a   Misset, J L ^a   Riofrio, M ^a   Guzman, C ^a   Brain, E ^a   Lopez Lazaro, L ^a   Rosing, H ^a   Jimeno, J M ^a   Cvitkovic, E ^a  

^a HÔPITAL PAUL BROUSSE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

TRABECTEDIN;

ADULT; AMINOTRANSFERASE BLOOD LEVEL; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BREAST CANCER; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOSE RESPONSE; HEPATOBILIARY DISEASE; HUMAN; LIPOSARCOMA; LIVER FUNCTION; MAJOR CLINICAL STUDY; MAXIMUM TOLERATED DOSE; NEUTROPENIA; OSTEOSARCOMA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SOLID TUMOR; THROMBOCYTOPENIA;

EID: 0035281641     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2001.19.5.1256     Document Type: Article

References (28)

1. Molecular and crystal structures of ecteinascidins: Potent antitumor compounds from the Caribbean tunicate Ecteinascidia turbinata
2. The NMR model of an ecteinascidin 743-DNA adduct
3. DNA sequence and structure selective alkylation of guanine N2 in the DNA minor groove by ecteinascidin-743, a potent antitumor compound from the Caribbean tunicate Ecteinascidin turbinata
4. Mode of action of ecteinascidin 743, a natural marine compound with antitumoral activity
5. Ecteinascidins (ET): A family of marine (MA) derived compounds with antineoplastic activity (AA)
6. ET743: Preclinical antitumor development of a marine derived natural product
7. In vitro antitumor activity of the novel marine agent, ecteinascidin-743 (ET-743, NSC-648766) against human tumors explanted from patients
8. Progress in the acquisition of new marine-derived anticancer compounds: Development of ecteinascidin-743 (ET-743)
9. Ecteinascidin 743, a transcription-targeted chemotherapeutic that inhibits MDR 1 activation
10. Isolation and characterization of an IGROV-1 human ovarian cancer cell line made resistant to ecteinascidin-743 (ET-743)
11. High antitumor activity of ET-743 against human tumor xenografts from melanoma, non-small-cell lung and ovarian cancer
12. In vivo antitumor activity of ecteinascidin-743 (ET-743), a novel marine derived cytotoxic against human xenograft tumor models
13. Ecteinascidin- 743, a new marine natural product with potent antitumor activity on human ovarian carcinoma xenografts
14. In vitro schedule-dependency of myelotoxicity and cytotoxicity of ecteinascidin 743 (ET-743)
15. Quantitative determination of ecteinascidin 743 in human plasma by miniaturized high-performance liquid chromatography coupled with electrospray ionization tandem mass spectrometry
16. Phase 1 clinical and pharmacokinetic (PK) study of ecteinascidin-743 (ET-743) given as a one hour infusion every 21 days
17. Ecteinascidin-743: A marine-derived compound in advanced, pretreated sarcoma patients - Preliminary evidence of activity
18. Phase II trial of docetaxel: A new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer
19. Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: High antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study
20. Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy
21. Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer
22. Identification of biochemical parameters that predict the onset of severe toxicities in patients treated with ET-743
23. Hepatic toxicity from cyclophosphamide, methotrexate, fluorouracil (CMF) regimen
24. The role of chemotherapy in the management of non-metastatic operable extremity osteosarcoma
25. Treatment of breast cancer
26. Mature results from three large controlled studies with raltitrexed (Tomudex)
27. Phase II trial of Tomudex (ZD 1694), a thymidylate synthetase inhibitor, in advanced pancreatic cancer
28. Factors predicting for efficacy and safety of docetaxel in a compassionate-use cohort of 825 heavily pretreated advanced breast cancer patients